AMAG Pharma (AMAG) Tops Q1 EPS by 29c; Boosts FY15 Revenue Outlook

AMAG Pharma (NASDAQ: AMAG) reported Q1 EPS of $1.17, $0.29 better than the analyst estimate of $0.88. Revenue for the quarter came in at $89.5 million versus the consensus estimate of $84.66 million.

AMAG Pharma sees FY2015 revenue of $395-430 million, versus prior guidance of $380-420 million and the consensus of $397.6 million.

For earnings history and earnings-related data on AMAG Pharma (AMAG) click here.

You May Also Be Interested In

• North American Construction (NOA) Tops Q2 EPS by 9c; Offers Guidance
• CAE, Inc. (CAE) Tops Q1 EPS by 2c, Beats on Revenue; Offers FY27 EPS Guidance
• Pan American Silver (PAAS) Misses Q2 EPS by 19c